Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-08-15
2010-11-02
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S135100, C424S158100, C435S069100, C435S320100, C435S325000, C435S328000, C435S336000, C435S007100, C435S007200, C530S350000, C530S387300, C530S388240, C530S391300, C536S023500
Reexamination Certificate
active
07824681
ABSTRACT:
Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.
REFERENCES:
Feng et al. (Mol. Cancer Ther. 2006; 5 (1): 114-120).
Kimura et al. (Clin. Cancer Res. 2010; 16: 121-129).
Bergmann et al., “Insulin-like growth factor II activates mitogenic signaling in pancreatic cancer calls via IRS-1: In vivo evidence for an islet-cancer cell axis,”International Journal of Oncology, 9:487-492 (1996).
Feng et al., “Noval human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGS receptor type I signal transduction function,” Molecular Cancer Therapeutics, 5(1):114-120, (Jan. 2006).
Geneseq, Accession No. GSN:ADR23364, “Human CD72-targeted IgG1 light chain,” retrieved from EBI, (Nov. 4, 2004).
Goya, “Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by Ligand-Specific Antibody to Human Insulin-Like Growth Factors,”Cancer Research, 64:6252-6258 (Sep. 1, 2004).
Miyamoto et al., “Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers,” Clinical Cancer Research, 11(9):3494-3502 (May 1, 2005).
Singh et al., “Proliferation and Differentiation of a Human Colon Cancer Cell Line (CaCo2) Is Associated with Significant Changes in the Expression and Secretion of Insulin-Like Growth Factor (IGF) IGF-II and IGF Binding Protein-4: Role of IGF-II,”Endocrinology, 137(5): 1764-1774 (1996).
Tanaka et al., “Identification of a Family of Insulin-Like Growth Factor II Secreted by Cultured Rat Epithelial-Like Cell Line 18,54-SF: Application of a Monoclonal Antibody,”Endocrinology, 124(2):870-877 (1989).
Yu and Rohan, “Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression,” Journal of the National Cancer Institute, 92(18):1472-1488, (Sep. 20, 2000).
Dimitrov Dimiter S.
Feng Yang
Klarquist & Sparkman, LLP
Rawlings Stephen L
The United States of America as represented by the Department of
LandOfFree
Human monoclonal antibodies that specifically bind IGF-II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies that specifically bind IGF-II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies that specifically bind IGF-II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243082